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Abstract 
Sarcomas are neoplastic malignancies that typically arise in tissues of mesenchymal origin. The identification 
of novel molecular mechanisms leading to sarcoma formation and the establishment of new therapies has 
been hampered by several critical factors. Human uterine leiomyosarcoma (Ut-LMS) develops more frequently 
in the muscle tissue layer of the uterine body than in the uterine cervix. Although the development of 
gynecologic tumors is often correlated with the secretion of female hormones; that of human Ut-LMS does 
not and its risk factors remain unknown. Importantly, a diagnostic biomarker that can distinguish malignant 
Ut-LMS from benign tumor uterine leiomyoma (LMA) has yet to be established. Therefore the risk factor(s) 
associated with human Ut-LMS to establish a diagnosis and novel therapeutic method. Proteasome b-ring 
subunit LMP2/b1i-deficient mice spontaneously develop Ut-LMS, with a disease prevalence of ~40% by 14 
months of age. We shown that LMP2/b1i expression was absent in human Ut-LMS, but present in other 
human uterine mesenchymal tumors including uterine LMA. Therefore, defective-LMP2/b1i expression may be 
one of the risk factors for human Ut-LMS. LMP2/b1i is a potential diagnostic biomarker for human Ut-LMS, 
and may be a targeted-molecule for a new therapeutic approach.  
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 Background 
 Sarcomas are a rare form of malignant tumor 
with less than 15,000 new cases diagnosed each year in 
United States. Though rare, sarcomas are highly 
debilitating malignancies as they are often associated 
with significant morbidity and mortality. Sarcomas are 
biologically very heterogeneous as evidenced by the 
fact that these malignant tumors arise from a plethora 
of different tissues and cell types. They are classically 
defined by their tissue of origin and additionally 
stratified by their histopathology or patient’s age at 
diagnosis. While most tumors of the uterine body are 
adenocarcinomas, tumors of uterine cervix are classified 
into squamous tumors and adenocarcinomas. Uterine 
mesenchymal tumors that develop in the myometrium 
have been traditionally divided into benign uterine usual 
LMA, cellular LMA and malignant Ut-LMS based on 
cytological atypia, mitotic activity, and other criteria. Ut-
LMS is relatively rare, having an estimated annual 
incidence of 0.64 per 100,000 women.1 Ut-LMS 
accounts for 2% ~ 5% of tumors of the uterine body 
and develops more frequently in the muscle layer of the 
uterine body than in the uterine cervix. As Surgical 
intervention is virtually the only means of treatment, 
because Ut-LMS is resistant to chemotherapy and 
radiotherapy.2,3 The prognosis for Ut-LMS is poor, and 
the five-year survival rate is approximately 35%. 
However, the development of an efficient adjuvant 
therapy is expected to improve the prognosis for human 
Ut-LMS. Uterine LMA may occur in 70% ~ 80% of 
women by the age of 50 years.4 Difficulties have been 
reported in distinguishing Ut-LMS from other uterine 
mesenchymal tumors including uterine LMA, and a 
diagnosis generally requires surgery and cytoscopy. 
Diagnostic categories for uterine mesenchymal tumors 
and morphological criteria are used to assign cases. The 
non-standard subtypes of uterine mesenchymal tumors 
such as the epithelioid and myxoid types are classified 
in a different manner using these features; therefore a 
diagnostic method that can identify non-standard 
smooth muscle differentiation needs to be 
established.5,6 
 High estrogen levels have been shown to 
significantly influence the development of tumors in the 
uterine body.7 Although the molecular mechanisms 
underlying the transformation of uterine LMA and Ut-
LMS develop remain unknown. The tumors that have 
been initiated and grown in the myometrium increase in 
size due to the influence of the female hormone, 
estrogen, and generate more tumors. However, no 
correlation has been reported between the development 
of Ut-LMS and hormonal conditions, and no obvious risk 
factors have been identified. Although cases 
accompanied by hypocalcaemia or eosinophilia have 
been reported, neither clinical abnormality is an initial 
risk factor for human Ut-LMS. The identification of a risk 
factor associated with the development of human Ut-
LMS would significantly contribute to the development 
of preventive and therapeutic treatments. 
 Cytoplasmic proteins are mostly degraded by a 
protease complex, which has many substrates 
consisting of twenty-eight 20 to 30 kDa subunits, 
referred to as the 20S proteasome.8,9 The proteasomal 
degradation is essential for many cellular processes, 
including the cell cycle, regulation of gene expression, 
and immunological function.10 Interferon (IFN)-g 
treatment induces the expression of large numbers of 
responsive genes, the b-ring subunits of proteasome, 
i.e., low-molecular mass polypeptide (LMP)2/b1i, LMP7/
b5i, and LMP10/multicatalytic endopeptidase complex-
like (MECL)-1/b2i.11 A molecular approach to studying 
the correlation of IFN-g with tumor cell growth has 
drawn attention. Homozygous mice deficient in LMP2/
b1i show tissue- and substrate-dependent abnormalities 
in the biological functions of the proteasome.12 Ut-LMS 
was reported in female LMP2/b1i-deficient mice at 6 
months or older, with its incidence at 14 months being 
approximately 40%.13 Histopathological studies of 
LMP2/b1i-lacking uterine tumors have revealed the 
characteristic abnormalities of Ut-LMS.13 These tumors 
consist of uniform elongated myometrium cells 
arranged into bundles. The nuclei of tumor cells vary in 
size and shape, and mitosis is frequent. In contrast, the 
myometrium cells of its parental mice, C57BL/6 mice 
were shown to be normal in appearance. Whereas 
relatively few ki-67-positive cells, the proliferating cells 
of solid tumors, have been reported in the basal cell 
layer of a normal myometrium, the expression of ki-67/
MIB1 was marked in most basal cells in LMP2/b1i-
deficient mice. 13 Marked body weight loss has been 
reported in LMP2/b1i-deficient mice that develop Ut-
LMS, and these mice die by 14 months of age. The 
LMP2/b1i-deficient mice also exhibit skeletal muscle 
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metastasis from Ut-LMS. Therefore, these research 
findings suggest that LMP2/b1i-deficient mice with Ut-
LMS die as a result of the tumor mass and metastasis.  
 The non-standard subtypes of uterine 
mesenchymal tumors such as the epithelioid and myxoid 
types are classified in a different manner using these 
features; therefore, a diagnostic method that can the 
identify non-standard smooth muscle differentiation 
needs to be established.5,6 Pathological studies have 
been  performed to demonstrate the validity and 
reliability of LMP2/b1i as a diagnostic biomarker when 
combined with other candidate molecules, such as cyclin 
E and calponin h1, which reportedly function as anti-
oncogenic factors in human Ut-LMS. Pathological 
examinations revealed that the ability to induce the 
expression of LMP2/b1i and calponin h1 was markedly 
lower in human Ut-LMS tissues than in uterine LMA or a 
normal myometrium located in the same section, and 
markedly expression of cyclin E in human Ut-LMS tissues 
only.14-17 Histological findings for the skeletal muscle and 
rectum lesions were consistent with metastatic Ut-
LMS.14,15 Western blotting and RT-PCR experiments 
revealed that LMP2/b1i was expressed in a normal 
myometrium, but not in human Ut-LMS, and both 
findings strongly supported the pathological 
results.14,15,17,18 Although we has previously 
demonstrated that abnormal expression of the ovarian 
steroid receptors, Tp53, ki-67 and mutations in Tp53 
were frequently associated with Ut-LMS, defective LMP2/
b1i expression appears to be more characteristic of 
human Ut-LMS than these factors.15,16 
 A female hormonal imbalance is often a risk 
factor for development of tumors in the case of 
gynecological cancers.7 As in the case of uterine LMA, 
however, a correlation between the development of Ut-
LMS, the female hormone, and hormone receptors has 
yet to be elucidated. Recent study reported the 
expression of Lmp2/b1i mRNA and protein in luminal 
and glandular epitheliua, placenta villi, trophoblastic 
shells, and arterial endothelial cells.19-21 These findings 
implicate LMP2/b1i in the invasion of placental villi, 
degradation of the extracellular matrix, immune 
tolerance, glandular secretion, and angiogenesis, but no 
more information for sarcomagenesis. Further studies 
should help to elucidate the molecular mechanism of 
human Ut-LMS tumorigenesis involved biological 
significance of LMP2/b1i; we are currently investigating 
the reliability and characteristics of LMP2/b1i as a 
diagnostic indicator with several clinical research 
facilities. Histopathological characteristics of human 
uterine mesenchymal tumors including mitotically active 
leiomyoma, bizarre leiomyoma, lipoleiomyoma, 
undifferentiated endometrial sarcoma, epithelioid variant 
leiomyosarcoma, myxoid variant leiomyosarcoma, 
smooth muscle tumors of uncertain malignant potential 
(STUMP), leiomyomatoid angiomatous neuroendocrin 
tumor (LANT) have been summarized already 22,23,24,25 
(Table 1, Table 2). Clarifying correlations between these 
factors and the development of human Ut-LMS and the 
identifying specific risk factors may lead to the 
development of new clinical treatments for the disease. 
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Table 2. LMP2 expression levels in human myome-
trium, uterine leiomyoma (Ordinaly leiomyoma, 
Cellular leiomyoma, Tumor of uncertain malignant 
potential), bizarre leiomyoma, uterine leiomyosar-
coma. IHC experiments individually performed at several 
medical facilities revealed a serious loss in the ability to 
induce LMP2/b1i expression in human uterine leiomyosar-
coma tissues compared to that in uterine leiomyoma or 
bizarre leiomyoma located in the same tissue section. 
Normal total: 59 cases, uterine leiomyoma total: 53 cas-
es, Bizarre leiomyoma total: 3 cases, uterine leiomyosar-
coma total: 59 cases. 
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Table 1. Differential protein expression in Uteriene tumours 
SMA, smooth muscle actin; MSA, muscle specific actin; ER/PR, estrogen receptor/ progesterone 
receptor; Endoglin, CD105/TGFb receptor (stem cell marker); EGFR, epidermal growth factor re-
ceptor; LMP2, low-molecular mass polypeptide; CD56, neural cell adhesion molecule (N-CAM); WT-
1, wilms tumor 1; NOS, not otherwise specified; MF, magnification factor; HPF, high power field; 
Foc., focal ; STUMP, smooth muscle tumors of uncertain malignant potential. Protein expression*, 
estimated-protein expressions by immunoblot analysis,  immunohistochemistry (IHC) and/or RT-
PCR (quantitative-PCR), +/-, partial expression; +, expression; ++, medium expression; +++, high 
expression; -, no evidence of expression; ER/PR(ref.16), LMP2(ref.14,15), cyclin E(ref.16,28), cal-
ponin h1(ref.17,26,27), Ki-67(ref.16,29). STUMP#(ref.29,30). Cyclin E, LMP2, calponin h1 are po-
tential bio-marker for human uterine mesenchymal tumours. LANT##, leiomyomatoid angiomatous 
neuroendocrin tumor (LANT) is desvribed as a dimorphic neurosecretory tumor with a leiomyoma-
tous vascular component (ref.22,23).   
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